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Abstract objectives To examine age differences in mortality and programme attrition amongst paediatric
patients treated in four African HIV programmes.
methods Longitudinal analysis of data from patients enrolled in HIV care. Two-year mortality
and programme attrition rates per 1000 person-years stratified by age group (<2, 2–4 and 5–
15 years) were calculated. Associations between outcomes and age and other individual-level factors
were studied using multiple Cox proportional hazards (mortality) and Poisson (attrition) regression
models.
results Six thousand two hundred and sixty-one patients contributed 9500 person-years; 27.1%
were aged <2 years, 30.1% were 2–4, and 42.8% were 5–14 years old. At programme entry, 45.3%
were underweight and 12.6% were in clinical stage 4. The highest mortality and attrition rates
(98.85 and 244.00 per 1000 person-years), and relative ratios (adjusted hazard ratio [aHR] = 1.92,
95% CI 1.56–2.37; incidence ratio [aIR] = 2.10, 95% CI 1.86–2.37, respectively, compared with the
5- to 14-year group) were observed amongst the youngest children. Increased mortality and attrition
were also associated with advanced clinical stage, underweight and diagnosis of tuberculosis at
programme entry.
conclusions These results highlight the need to increase access, diagnose and provide early HIV
care and to accelerate antiretroviral treatment initiation for those eligible. Adapted education and
support for children and their families would also be important.
keywords antiretroviral treatment, children, HIV, outcome assessment, Africa
Introduction
The provision of paediatric HIV care in resource-limited
settings has expanded significantly over the last decade.
At the end of 2010, 456 000 children were receiving
combined antiretroviral therapy (ART) in low- and
middle-income countries. However, treatment coverage
amongst children requiring therapy remains low. In
2010, UNAIDS estimated that, globally, only 23% of
children in need of ART received it, compared with 47%
of adults (WHO 2011). Factors limiting the access of
HIV-infected children to ART are multiple and include
poor integration of HIV care with maternal and child
health services, insufficient access to early infant diagno-
sis, implementation of strategies inefficient for retaining
HIV-infected mothers and their children in care, and staff
and caregivers who have often lacked of confidence and
training to deal with children infected with HIV, espe-
cially during the early years of care provision when no
adapted paediatric galenic antiretroviral formulations
were available. Whilst progress in addressing these
factors has been made over the last 10 years with
initiatives, such as the development and commercialisa-
tion of paediatric fixed-dose combinations of antiretrovi-
ral drugs, the writing up of specific and increasingly
simplified guidelines for the management of paediatric
HIV infection training of health workers and, more
recently, roll out of improved diagnostic technologies
such as HIV deoxyribonucleic acid polymerase chain
reaction (DNA PCR) using dried blood spot, substantial
gaps in implementation exist.
Reassuringly, an increasing number of studies have
reported treatment outcomes in children who are
diagnosed and initiated on ART that are comparable, if
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not better than those of children treated in North Amer-
ica or Europe (Sutcliffe et al. 2008). Medecins Sans
Frontieres (MSF) began providing HIV care to adults in
resource-limited settings in 2000 and to children in 2001.
In this study, we examine the first 10 years of experience
in treating paediatric HIV infection in sub-Saharan Africa
by describing the clinical characteristics of children who
enrolled in HIV care during this period and reporting
treatment and programme outcomes 2 years after
programme inclusion. Differences in patient mortality by
age group and associations with other individual-level
factors are also investigated to optimise patient management.
Methods
Study sites and population
The four HIV programmes supported by the French sec-
tion of MSF were included in the evaluation: one from
Uganda, one from Malawi and two from Kenya. Three
were located in HIV clinics of district hospitals in rural
areas, one of them with care highly decentralised to
peripheral health centres, and were implemented in
collaboration with the respective Ministries of Health,
and one in an HIV clinic in a slum of Nairobi that was
run by MSF alone. HIV care provision to children in
these sites started between April 2001 and September
2002. All services related to HIV care, including
laboratory testing, provision of combined antiretroviral
therapy (ART), management of opportunistic infections
and hospitalisation, were free.
For children aged >18 months, the diagnosis of HIV
was based on the existence of two positive HIV rapid
antibody tests. Younger children were diagnosed using
HIV DNA PCR on dried blood spot when it was avail-
able and, when it was not, diagnosis was based on clini-
cal and immunological criteria as recommended by the
World Health Organization (WHO) and later confirmed
with rapid antibody testing. Daily cotrimoxazole prophy-
laxis was prescribed, and ART eligibility was determined
in accordance with WHO treatment guidelines. Medical
visits for children ineligible for ART were generally
scheduled every 3–6 months, or more frequently if clini-
cally indicated. Visits for children receiving ART were
scheduled at least monthly during the first 6 months and
then every 2–3 months after clinical stabilisation. Group
and individual counselling for caregivers and children,
including therapeutic education and adherence support,
were provided by peer workers and trained counsellors.
Routine CD4 count testing was performed every
6–12 months before and after starting ART. Because of
limited availability and cost constraints, viral load testing
was reserved to cases of suspected treatment failure.
However, in the clinic in Nairobi, routine viral monitor-
ing was gradually introduced for children in 2007.
Study design and data collection
All children (<15 years) who entered in one of the four
HIV programmes between 8 April 2001 and 22 Decem-
ber 2010 and had attended two or more clinic visits were
included in the analysis.
In agreement with the respective Ministries of Health,
socio-demographic, clinico-immunological and treatment
information were routinely recorded on medical files and
entered into an electronic database (FUCHIA; Epicentre,
Paris, France). Regular data consistency checks and verifi-
cations of key information (e.g. dates of birth, sex, date
of ART start, CD4 cell count and percentage measures)
were regularly performed on and off site to ensure the
quality of the data.
Statistical analysis
Patient characteristics at programme entry were described
with summary statistics (proportions and medians with
interquartile ranges), stratified by age group (<2, 2–4 and
5–15 years). Patient follow-up started at programme
inclusion and was right-censored at the earliest of the
following dates, transfer outside the HIV programme, last
medical visit, or 24 months after programme entry. The
duration of follow-up was split into three time periods:
pre-ART, 0–6 and 6–24 months after ART start. Age-
specific rates of mortality and programme attrition
(deaths and lost to follow-up) expressed per 1000 person-
years with 95% CI were calculated 3, 6, 12 and
24 months after programme entry. Patients lost to
follow-up were those with a date of appointment not
attended for more than 2 months, or patients with no
date of next appointment not seen for more than
12 months (or for more than 6 months if they had
started ART).
After verifying the proportional hazard assumption
using the test of proportionality, multivariable Cox
models were used to examine differences in 2-year
mortality by age group. Crude and adjusted hazard ratios
(HR) with 95% confidence interval (CI) were estimated.
The following were factors considered in adjusted analy-
ses: study site, sex, age group and year of programme
entry (2001–2004, 2005–2007 and 2008–2010); baseline
WHO clinical stage (1, 2, 3, 4 and missing), underweight
status (no, yes and missing) and tuberculosis diagnosis;
and period of follow-up (pre-ART, <6 months and
6–24 months after ART start). Underweight was defined
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as a weight-for-age score of <2 for children aged
<5 years old, and an age- and sex-specific body mass
index (BMI) value equivalent to the <18.5 cut-off points
of adults for children aged 5–14 years old (Cole et al.
2007). All individual-level factors associated with the
outcome (P < 0.2) in univariable analysis were included
in the final multivariable models. The likelihood ratio test
for association was used, and the level of statistical
significance considered was P < 0.05. The fit of the final
models was assessed with the goodness-of-fit test for
Cox.
Several sensitivity analyses were performed: first using
competing risk analysis to account for the possible lack
of independence between patients’ risk of mortality and
loss to follow-up; and second restricting analyses to
patients with complete case data. The association
between 2-year programme attrition and age was also
investigated using multivariable Poisson regression using
first information from all patients and then complete case
data only. All analyses were carried out with Stata 11
(Stata Corp, College Station, Texas, USA).
Results
Patient characteristics
The analyses included the 6261 paediatric patients who
had more than one recorded medical visit (Figure 1) and
contributed 9500 person-years of follow-up. Patient
median age at programme entry was 4 years, with 27.1%
of patients being aged <2 years, 30.1% aged 2–4 years
and 42.8% aged 5–14 years (Table 1). 51% of patients
were females. The primary modes of entry in the pro-
gramme were through voluntary counselling and testing
(47.0%) or medical referral (42.7%). Less than 0.2% of
children aged 2–14 years had history of prevention of
mother-to-child transmission (PMTCT) prophylaxis use,
whereas 5.9% of those in the <2-year age group did. And
the number of young children with recorded PMTCT
exposure gradually increased from 2005 to 2008 (5 and
32 children, respectively) and then slightly decreased
again (down to 16 in 2010). Tuberculosis had been
diagnosed in 9.8% of patients at the time of programme
entry. Overall, 46.3% of patients presented in clinical
stage 3 or 4, and 45.3% were underweight. No
differences in severity of clinical presentation were
observed across the three age groups, but tuberculosis
was diagnosed more often after the first 2 years of age.
Mortality and programme attrition by age group
During the study period, 557 patients died and 1142
were lost to follow-up. Two-year mortality was higher in
children aged <2 years than in older children (98.85
compared with 43.47 per 1000 person-years in the 2- to
4-year group; and 46.16 per 1000 person-years in the
5- to 14-year group). Adjusted HR (aHR) were 1.92,
95% CI 1.56–2.37 for the <2-year group and 0.87, 95%
CI 0.69–1.10 for the 2- to 14-year group, compared with
children aged 5–14 years (Table 2). Similar results were
obtained when competing risks models were used
(adjusted sub-hazard ratio (aSHR) = 1.99, 95% CI
1.61–2.47 and aSHR = 0.96, 95% CI 0.76–1.21, respec-
tively, compared with the 5- to 14-year group).
Two-year attrition was also higher amongst children of
<2 years [244.00 compared with 164.65 per 1000 per-
son-years in the 2- to 4-year group; and 151.40 per 1000
person-years in the 5- to 14-year group (Table 3)].
Adjusted IR (aIR) = 2.10, 95% CI 1.86–2.37 and
aIR = 1.28, 95% CI 1.13–1.44, respectively, compared
with the 5- to 14-year group.
Restriction of analyses to patients with complete case
data did not change the results for mortality or pro-
gramme attrition. Rates of mortality and attrition were
higher during the first 6 months of ART and gradually
decreased over time after this period (Figure 2).
Other factors associated with programme attrition and
mortality
Advanced clinical disease presentation (aHR = 1.68,
95% CI 1.28–2.20 for stage 3; and aHR = 2.47, 95% CI
3965 (63.3%) started on ART 
6261 (93.4%) included in analysis 
6682 paediatric patients in the 
study HIV programs 
421 (6.3%) with only 1 medical visit 
2296 (36.7%) never started on ART Figure 1 Flowchart of patients included
in the analysis.
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1.80–3.38 for stage 4; compared with patients with stage 1),
underweight (aHR = 2.12, 95% CI 1.76–2.54) and tuber-
culosis diagnosis (aHR = 1.61, 95% CI 1.26–2.05) were
strongly associated with increased risk of mortality.
Higher mortality was also observed during the first
6 months of ART and lower in the 6–24 months after
ART initiation (aHR = 5.55, 95% CI 4.50–6.84; and
aHR = 0.19, 95% CI 0.15–0.24, respectively, compared
with the pre-ART period) and during early years of pro-
gramme activity for children aged 2 years or more
[aHR = 2.21, 95% CI 1.26–3.86 and aHR = 2.03, 95%
CI 1.25–3.29 for the periods 2001–2004 and 2005–2007,
respectively, compared with 2008–2010 in the 2–4 age
group; and 2.46, 95% CI 1.60–3.77 and 1.92, 95% CI
1.27–2.09, respectively, in the 5–12 age group (Table 3)].
The same associations were identified when competing
risks regression, and complete case data analyses were
performed. Nevertheless, the size of the effects estimated
in sensitivity analyses was smaller for advanced clinical
disease (clinical stages 3 and 4 and underweight) and for
the period of follow-up on ART. And stronger effects
were also observed for year of programme entry in the
complete case analysis.
Similarly, higher risk of programme attrition was
observed in patients with severe clinical disease
(aHR = 1.75, 95% CI 1.51–2.03 for stage 3; and
aHR = 3.06, 95% CI 2.56–3.66 for stage 4), under-
weight (aHR = 1.61, 95% CI 1.45–1.78) and tuberculo-
sis diagnosis at programme entry (aHR = 1.31, 95% CI
1.12–1.54). The risk of attrition was also higher during
the first 6 months of ART use and lower in the following
18 months (aHR = 2.43, 95% CI 2.16–2.74; and
aHR = 0.09, 95% CI 0.08–0.11, respectively, compared
with the follow-up period before ART start). Results
from analyses restricted to patients with complete case
data were similar (Table 4), although the association
with year of programme entry was only seen for the older
age group of children (Table 3).
Discussion
In this study conducted amongst 6261 paediatric patients
who were receiving HIV care in four large HIV pro-
grammes in sub-Saharan Africa over a 10-year period,
fewer than 5% had a history of PMTCT prophylaxis use
and medical referral was the mode of entry in two of five
Table 1 Patient characteristics at programme entry stratified by age group
Characteristics
<2 years
N = 1698
2–4 years
N = 1885
5–14 years
N = 2678
Total
N = 6261
Female, n (%) 836 (49.2) 921 (48.9) 1440 (53.8) 3197 (51.1)
Median age, [IQR] 1.0 [0.4–1.4] 3.0 [2.3–4] 8.0 [6.3–11.0] 4.0 [1.8–7.7]
Mode of programme entry, n (%)
Medical referral 629 (43.9) 715 (43.3) 965 (41.6) 2309 (42.7)
Volunteer counseling and testing 564 (39.4) 802 (48.5) 1175 (50.6) 2541 (47.0)
Other 240 (16.7) 136 (8.2) 182 (7.8) 558 (10.3)
Missing 265 232 356 853
History of PMTCT prophylaxis use, n (%) 100 (5.9) 3 (0.2) 3 (0.1) 106 (1.7)
Clinical stage, n (%)
1 426 (41.7) 527 (35.2) 635 (29.4) 1588 (33.9)
2 150 (14.7) 273 (18.2) 505 (23.3) 928 (19.8)
3 323 (31.6) 512 (34.2) 741 (34.3) 1576 (33.7)
4 123 (12.0) 185 (12.4) 282 (13.0) 590 (12.6)
Missing 676 388 515 1579
Tuberculosis diagnosis, n (%) 126 (7.4) 197 (10.5) 290 (10.8) 613 (9.8)
Median weight, kg [IQR] 7.0 [5.7–8.6] 11.0 [9.0–13.0] 20.0 [16.0–24.5] 12.0 [8.5–19.0]
Missing, n (%) 3 (0.2) 3 (0.2) 5 (0.2) 11 (0.2)
Underweight, n (%)
No 1015 (59.9) 954 (50.7) 1360 (54.1) 3329 (54.7)
Yes 680 (40.1) 928 (49.3) 1153 (45.9) 2761 (45.3)
Missing 3 3 165 171
Median CD4 cell count, cells/ll [IQR] 957 [544–1411] 706 [412–1063] 400 [189–682] 574 [299–974]
Missing, n (%) 864 (50.9) 615 (32.6) 814 (30.4) 2293 (36.6)
Median CD4 percentage [IQR] 17.0 [10.8–25.0] 17.4 [10.7–25.0] 13.0 [6.4–23.0] 16.2 [10.0–24.7]
Missing, n (%) 908 (53.5) 732 (38.8) 1990 (74.3) 3630 (58.0)
IQR, interquartile range; PMTCT, prevention of mother-to-child transmission of HIV infection.
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patients. Mortality and attrition during the first two years
of follow-up in HIV care were two times higher amongst
the youngest children than amongst those aged five to
fourteen years. Advanced clinical disease presentation,
underweight and tuberculosis diagnosis were strongly
associated with poor patient outcomes. Higher rates were
Table 2 Association between mortality and selected individual-level factors
Factors
No.
of deaths
Mortality rate
per 1000 PY
All patient data Competing risks Complete case
Crude HR Adjusted HR Adjusted SHR Adjusted HR
Site P = 0.13 P < 0.001 P = 0.02 P < 0.001
Uganda 87 47.55 (38.54–58.67) 1 1 1 1
Malawi 325 60.94 (54.66–67.94) 1.30 (1.03–1.65) 1.18 (0.92–1.51) 1.28 (0.98–1.66) 1.69 (1.24–2.31)
Kenya – rural 82 61.58 (49.60–76.47) 1.32 (0.97–1.78) 0.89 (0.65–1.21) 0.89 (0.65–1.23) 1.07 (0.74–1.56)
Kenya – urban 63 62.63 (48.92–80.17) 1.32 (0.95–1.82) 1.23 (0.88–1.72) 1.30 (0.93–1.83) 1.58 (1.09–2.30)
Sex P = 0.01 P < 0.001 P = 0.02 P = 0.06
Male 301 65.35 (58.37–73.16) 1 1 1 1
Female 256 52.31 (4628–59.13) 0.81 (0.68–0.95) 0.84 (0.71–1.00) 0.82 (0.69–0.97) 0.82 (0.67–1.01)
Age group P < 0.001 P < 0.001 P < 0.001 P < 0.001
5–14 years 193 46.16 (40.01–53.16) 1 1 1 1
2–4 years 127 43.47 (36.53–51.73) 0.94 (0.75–1.18) 0.87 (0.69–1.10) 0.96 (0.76–1.21) 0.93 (0.72–1.21)
<2 years 237 98.85 (87.03–112.27) 2.07 (1.71–2.51) 1.92 (1.56–2.37) 1.99 (1.61–2.47) 1.83 (1.43–2.35)
Clinical stage P < 0.001 P < 0.001 P = 0.02 P = 0.05
1 98 39.48 (32.39–48.12) 1 1 1 1
2 51 35.25 (26.79–46.38) 0.90 (0.64–1.26) 1.04 (0.74–1.46) 0.98 (0.70–1.37) 0.92 (0.66–1.30)
3 169 72.33 (62.21–84.10) 1.83 (1.43–2.35) 1.68 (1.28–2.20) 1.39 (1.06–1.83) 1.27 (0.96–1.68)
4 90 119.64 (97.31–147.10) 2.98 (2.24–3.97) 2.47 (1.80–3.38) 1.67 (1.20–2.33) 1.52 (1.08–2.13)
Missing 149 60.03 (51.13–70.49) 1.53 (1.19–1.98) 1.24 (0.95–1.61) 1.25 (0.96–1.64) –
Tuberculosis
diagnosis
P < 0.001 P < 0.001 P < 0.001 P < 0.001
No 453 52.39 (47.78–57.44) 1 1 1 1
Yes 104 121.89 (100.58–147.72) 2.29 (1.85–2.83) 1.61 (1.26–2.05) 1.68 (1.28–2.20) 1.63 (1.23–2.16)
Underweight P < 0.001 P < 0.001 P < 0.001 P < 0.001
No 216 41.18 (36.04–47.06) 1 1 1 1
Yes 317 78.55 (70.36–87.69) 1.88 (1.58–2.24) 2.12 (1.76–2.54) 1.64 (1.36–1.98) 1.69 (1.35–2.12)
Missing 24 109.37 (73.31–163.18) 2.48 (1.68–3.65) 2.06 (1.31–3.25) 1.76 (1.11–2.78) –
Period of follow-up P < 0.001 P < 0.001 P < 0.001 P < 0.001
Pre-ART 200 70.14 (61.06–80.56) 1 1 1 1
ART <6 months 238 664.03 (584.81–753.98) 8.14 (6.70–9.90) 5.55 (4.50–6.84) 4.83 (3.88–6.01) 4.18 (3.21–5.44)
ART ≥6 months 119 18.92 (15.81–22.64) 0.28 (0.22–0.35) 0.19 (0.15–0.24) 0.31 (0.24–0.38) 0.31 (0.23–0.40)
HR, hazard rate ratio; PY, person-years of follow-up; SHR, sub-hazard rate ratio.
Table 3 Changes in associations between mortality and attrition over time stratified by age group
<2 years 2–4 years 5–15 years
No. of deaths Adjusted HR No. of deaths Adjusted HR No. of deaths Adjusted HR
Mortality
2001–2004 28 0.73 (0.47–1.14) 35 2.21 (1.26–3.86) 74 2.46 (1.60–3.77)
2005–2007 93 0.95 (0.70–1.27) 67 2.03 (1.25–3.29) 75 1.92 (1.27–2.09)
2008–2010 116 1 25 1 44 1
Attrition
2001–2004 88 0.80 (0.62–1.04) 130 1.17 (0.90–1.53) 207 1.14 (0.92–1.41)
2005–2007 231 0.85 (0.70–1.03) 208 0.99 (0.79–1.24) 234 1.63 (1.30–2.06)
2008–2010 266 1 143 1 192 1
P-value for likelihood ratio test for interaction between age group and year of programme entry was <0.001 for mortality and for attrition.
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Figure 2 Mortality and attrition rates by age group and time since programme entry.
Table 4 Association between attrition and selected individual-level factors
Factors
No. of
deaths
Attrition rate
per 1000 PY
All patient data
Complete case
Crude IR Adjusted IR Adjusted IR
Site P < 0.001 P = 0.003 P = 0.005
Uganda 351 191.85 (172.80–213.01) 1 1 1
Malawi 870 163.14 (152.65–174.35) 0.85 (0.75–0.96) 0.91 (0.80–1.04) 0.94 (0.81–1.09)
Kenya – rural 287 215.54 (191.99–241.98) 1.12 (0.96–1.31) 1.03 (0.88–1.21) 1.10 (0.91–1.31)
Kenya – urban 191 189.87 (164.76–218.80) 0.99 (0.83–1.18) 1.26 (1.05–1.51) 1.30 (1.07–1.58)
Sex P = 0.22 P = 0.13 P = 0.57
Male 849 184.31 (172.32–197.14) 1 1 1
Female 850 173.70 (162.40–185.77) 0.94 (0.86–1.04) 0.93 (0.84–1.02) 0.97 (0.87–1.08)
Age group P < 0.001 P < 0.001 P < 0.001
5–14 years 633 151.40 (140.05–163.67) 1 1 1
2–4 years 481 164.65 (150.57–180.04) 1.09 (0.97–1.22) 1.28 (1.13–1.44) 1.29 (1.12–1.47)
<2 years 585 244.00 (225.01–264.59) 1.61 (1.44–1.80) 2.10 (1.86–2.37) 2.10 (1.82–2.41)
Clinical stage P < 0.001 P < 0.001 P < 0.001
1 352 141.80 (127.74–157.42) 1 1 1
2 219 151.37 (132.60–172.81) 1.07 (0.90–1.26) 1.26 (1.06–1.49) 1.24 (1.04–1.47)
3 476 203.72 (186.22–222.87) 1.44 (1.25–1.65) 1.75 (1.51–2.03) 1.70 (1.46–1.99)
4 246 327.02 (288.61–370.55) 2.31 (1.96–2.71) 3.06 (2.56–3.66) 3.07 (2.55–3.70)
Missing 406 163.57 (148.41–180.28) 1.15 (1.00–1.33) 1.11 (0.96–1.29) –
Tuberculosis diagnosis P < 0.001 P < 0.001 P = 0.007
No 1474 170.47 (161.99–179.40) 1 1 1
Yes 225 263.71 (231.41–300.52) 1.55 (1.34–1.78) 1.31 (1.12–1.54) 1.26 (1.07–1.49)
Underweight P < 0.001 P < 0.001 P < 0.001
No 786 149.86 (139.75–160.72) 1 1 1
Yes 852 211.11 (197.40–225.78) 1.41 (1.28–1.55) 1.61 (1.45–1.78) 1.63 (1.45–1.83)
Missing 61 277.99 (216.30–357.29) 1.92 (1.50–2.46) 2.43 (1.83–3.22) –
Period of follow-up P < 0.001 P < 0.001 P < 0.001
Pre-ART 974 341.56 (320.77–363.69) 1 1 1
ART <6 months 443 1235.98 (1126.09–1356.61) 3.62 (3.23–4.05) 2.43 (2.16–2.74) 2.39 (2.07–2.75)
ART ≥6 months 282 44.83 (39.90–50.39) 0.13 (0.11–0.15) 0.09 (0.08–0.11) 0.09 (0.08–0.11)
IR, incidence rate ratio; PY, person-years of follow-up.
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observed in earlier years of programme activity and
during the first six months of ART use and lower in the
following 18 months of therapy.
In our study, patients aged <2 years represented 27%
of the total number of children accessing HIV care. This
figure is lower than proportions reported in other studies,
where patients aged <2 years represented almost 40% of
the total number of children accessing HIV care (Sutcliffe
et al. 2011; Munyagwa et al. 2012). And this highlights
the limited access that young children have to HIV test-
ing and counselling in the study area. Poor access is likely
to be related to a combination of inadequate access to
PMTCT services, limited diagnostic capacity, especially
during early years of programme activity and/or poor
linkage to HIV services after diagnosis.
Besides the technological barriers to earlier enrolment
of children into HIV care, the poor integration of HIV
and maternal child health services means that opportuni-
ties to detect infected mothers and their infants are
often missed. Almost half of the total number of
children included in our analysis entered HIV care via
medical referral. This finding suggests that new strate-
gies to expand access to early HIV testing are needed to
bring children into care before they are sick. Approaches
that engage maternal and child health services, integra-
tion of VCT in outpatient services to facilitate HIV test-
ing of sick children, or community-based testing need to
be further developed and evaluated. As new more effec-
tive PMTCT interventions such as the option B+ (provi-
sion of uninterrupted ART to pregnant women
irrespective of patient eligibility for therapy) are imple-
mented, it is expected that a minority of children born
to mothers attending PMTCT services will acquire HIV
infection, and therefore, most infants diagnosed with
HIV will no longer be identified in PMTCT
programmes.
The low proportion of children with documented
exposure to prophylaxis for PMTCT of HIV in the
programmes evaluated may reflect underreporting of
prophylactic use, low rates of HIV infection amongst
PMTCT users and/or sub-optimal access to PMTCT
care. It also reflects the important challenges faced by
care providers to implement effective PMTCT pro-
grammes in Africa. Given that, in the absence of ART
use, approximately half of perinatally infected children
die before the age of 2 years(Newell et al. 2004;
Penazzato et al. 2012), it is likely that in areas covered
by the programmes evaluated, many HIV-infected
children died without ever being recognised as infected
with HIV.
Mortality and attrition observed in these cohorts of
children was higher than amongst older patients, a find-
ing consistent with previous studies (Raguenaud et al.
2009; Sutcliffe et al. 2011; McNairy et al. 2012). It is
now well accepted that there are significant benefits in
terms of mortality and morbidity reduction and
improved general psychomotor development associated
with early rather than deferred ART (Violari et al. 2008;
Goetghebuer et al. 2012; Laughton et al. 2012).
However, as the results of this study show, in reality,
there continues to be many missed opportunities or gaps
to access, diagnose and treat young children with HIV
early enough to achieve this reduction in risk. Globally,
in 2010, data from 65 low- and middle-income countries
showed that only an estimated 28% of HIV exposed
infants had access to early infant diagnosis (WHO 2011).
Improving access to point of care testing at 6 weeks of
age as recommended by WHO would be a significant
step forward and could lead to earlier treatment initia-
tion and reduced mortality of infants infected in utero
(Sherman 2012).
As for adults, studies have shown that a large propor-
tion of children lost to follow-up (12–87% in African set-
tings) may be unrecorded deaths (McGuire et al. 2012).
Besides reflecting mortality, the particularly high lost to
follow-up rate amongst infants is likely to reflect the diffi-
culties faced by HIV-infected women with young children
who need to deal with their own status and that of their
child. Financial family constraints and parental disease or
death related to HIV infection are also likely to lead to
delays in paediatric care and contribute to increased mor-
tality and dropouts. Adapted counselling strategies and
support structures for women and their families are often
not sufficiently in place (Hassan et al. 2012).
Children aged 5–14 years constitute an important
group amongst those enrolled in HIV care. These ‘long-
term survivors’ have particular needs that are usually not
adequately met in resource-limited settings. Whilst they
do not have the same mortality risk as younger children
as shown by this study and others (Charlebois et al.
2010; Fenner et al. 2010), they face significant
morbidities, including risk of poor physical and neurode-
velopmental growth, poor sexual maturation and risk of
chronic lung disease (Smith et al. 2012). Furthermore,
from a social perspective, this group of children has a
higher likelihood of being orphaned and often struggles
with challenges in their home life as well as at school,
which has implications for their adherence to treatment
(Williams et al. 2006).
The observed decrease in mortality over time amongst
children may be attributed to progressive enrolment of
children at younger ages and at earlier stages of disease.
In addition, it may also reflect improvement in clinical
management as clinicians acquire more experience and as
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new guidelines including updated recommendations are
published and implemented. In the early 2000s, there
was little guidance on how to best care for children
infected with HIV infection. The first WHO guideline
specifically concerning the care of HIV positive children
was published in 2006. After the publication of results
from the CHER study, in 2008, WHO recommended
treating all infants before the age of 1 year, regardless of
clinical or immunological status (Violari et al. 2008;
Puthanakit & Bunupuradah 2010; WHO 2010). The
findings of our study show that, despite the achievements
of recent years, there is still a need to reduce deaths and
lost to follow-up amongst children through earlier HIV
diagnosis, proper screening and treatment for opportunis-
tic infections such as tuberculosis, earlier start of ART
and adequate education and counselling for children and
their caregivers to maximise retention in care. Progres-
sively increasing the age threshold for the systematic ini-
tiation of therapy of children older than one year might
be a pragmatic strategy to simplify paediatric HIV care
provision and improve patient outcomes by reducing
delays in ART start, mortality and lost to follow-up
rates.
Finally, advanced clinical disease, underweight and
tuberculosis diagnosis at enrolment were strongly associ-
ated with increased risk of mortality or attrition. These
findings are similar to those of previous studies (Mun-
yagwa et al. 2012; Sutcliffe et al. 2011; Raguenaud et al.
2009; Fenner et al. 2010; Cross Continents Collabora-
tion for Kids (3Cs4kids) Analysis & Writing Committee
2008; Wamalwa et al. 2012). Tuberculosis is an opportu-
nistic infection frequently associated with HIV infection
in adults and children and associated with increased
mortality (Kyeyune et al. 2010; Bakeera-Kitaka et al.
2011). However, the burden of tuberculosis in both HIV-
infected and HIV-uninfected children is significantly
underestimated due to the difficulties of diagnosis
(Kyeyune et al. 2010; Bakeera-Kitaka et al. 2011).
Paediatric HIV infection is associated with a 20-fold
increased risk of developing active tuberculosis (Hesseling
et al. 2009). In our analysis, 9.8% of all children were
diagnosed with tuberculosis at the time of enrolment in
HIV care. Based on results from other studies conducted
amongst adults and children living in the same geograph-
ical areas, this figure is likely to underestimate the true
burden of disease amongst children (Shah et al. 2009;
Bakeera-Kitaka et al. 2011). Published research (Bakeera-
Kitaka et al. 2011; Marais et al. 2011) suggests that
undiagnosed tuberculosis is likely to have contributed to
the high mortality observed before and in the 6 months
following ART start.
Several limitations need to be considered when inter-
preting the results of this evaluation. First, we used elec-
tronic health records with missing CD4 counts for most
of the children and probable underreporting of PMTCT
exposure. Nevertheless, the results obtained in the
complete case data analysis, although generally of smaller
size, were consistent with those estimated in primary
analyses. Second, as shown in previous studies (McGuire
et al. 2010; Desmonde et al. 2011), it is likely that many
of the children lost to follow-up were unreported deaths,
resulting in underestimation of mortality. However,
competing risk analyses and those examining the
association between baseline factors and retention in care
were consistent with results of primary analyses. Third,
we cannot exclude residual confounding by unmeasured
factors such as information on family support and
caregiver, which are likely to be associated with mortality
(Sutcliffe et al. 2011). Finally, we excluded 6% of
patients who had a unique clinic visit and were more
likely to have advanced clinical disease, be underweight
and to have died (Table S1). This might have resulted in
some underestimation of study effects.
Conclusion
The results of this large study conducted under program-
matic conditions and over a 10-year period add to our
understanding of the challenges faced in the initial years
of treating paediatric HIV infection in sub-Saharan
African and of the evolution of public health programmes
over time. Whilst good progress has been made in generat-
ing evidence through field research, creating practical
guidance and developing adapted diagnostic tools and
drug formulations for children, there remains significant
work still to do. This study highlights the need to increase
access, diagnose and provide early HIV care to children
and to accelerate ART initiation for those eligible. It also
stresses the importance of finding better ways to increase
HIV testing of high-risk group children (e.g. amongst
chronically ill and/or malnourished), effectively screen for
and treat opportunistic infections, especially tuberculosis,
and of ensuring that education and support are adapted to
the needs of the children and their family.
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